In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Share, Licensing, and M&A: Three's Company

Executive Summary

Achieving 10% global market share--Richard Sykes' stated rationale for pursuing another merger for Glaxo--won't accomplish what he wants: sustainable profitability. In the first place, pharmaceutical market share is important largely within categories; in the second, M&A works against achieving significant category share. Not only are antitrust authorities likely to force divestitures within categories; but M&A disrupts in-licensing, so far the only proven supplement to internal R&D for creating major players within categories.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts